Broad Clinical Labs is a clinical diagnostics organization affiliated with the Broad Institute of MIT and Harvard, based in Cambridge, Massachusetts. It focuses on high‑throughput molecular testing and genomic analysis, applying automation and next‑generation sequencing alongside PCR to deliver scalable, rapid laboratory services. The lab emerged from the Broad Institute’s large‑scale diagnostic and surveillance efforts, notably during the COVID‑19 pandemic, and continues to support healthcare providers, universities, and public health agencies with population‑level testing and data reporting.
Its work spans assay development and validation, routine molecular diagnostics (such as respiratory pathogen testing), and sequencing‑based surveillance that helps track pathogen evolution and spread. Broad Clinical Labs operates under clinical regulatory standards (e.g., CLIA) and integrates with partner workflows for sample logistics, informatics, and results delivery. The lab’s capabilities are used in both clinical and public health contexts to provide reliable, high‑volume testing and actionable genomic insights.
None yet. When a new project in the record names Broad Clinical Labs as owner, partner or investor, it shows here.
New single-molecule platform uses SBX chemistry and reusable CMOS nanopore sensors to deliver same-day whole‑genome sequencing, open-source analysis and flexible workflows.
